Classifications

• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
  • G01N33/6848—Methods of protein analysis involving mass spectrometry
  • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
  • G01N33/6848—Methods of protein analysis involving mass spectrometry
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
  • G01N33/6806—Determination of free amino acids
  • G01N33/6812—Assays for specific amino acids

Definitions

• sequence listing in electronic format.
• the sequence listing provided as a file titled, “55797_Seqlisting.txt,” created September 20, 2021 , and is 7,091 bytes in size.
• the information in the electronic format of the sequence listing is incorporated herein by reference in its entirety.
• PTMs protein post-translational modifications
• arginine methylation 1 phosphorylation 2
• ubiquitination 3 glycosylation 4-5
• glycosylation 4-5 O-linked p-N- acetylglucosamine modification 6-7 in the biology of the cell
• proteins can also undergo spontaneous chemical degradation, readily detectable after aging or under stressed conditions 9 .
• the current literature contains many studies on the characterization of such chemical modifications identified in both cellular proteins and biotherapeutics 10-12 . Examples of such chemical modifications include methionine and tryptophan oxidation, asparagine deamidation, as well as aspartate isomerization 13-16 .
• the method comprises: (a) digesting a protein into peptides, (b) subjecting the peptides to mass spectrometry and measuring fragmentation, by mass spectrometry (such as tandem-mass spectrometry (MS/MS)), of a peptide bond N-terminal to an /soaspartic acid (/soAsp); (c) comparing the fragmentation to a threshold, wherein the fragmentation exceeding the threshold is indicative of the presence of the /soAsp in the peptide being analysed and ultimately in the protein.
• the methods further comprise the (d) rejecting the protein comprising the /soAsp, or engineering the protein to remove the /soAsp.
• the methods described herein further comprises reducing the charge (z) of the peptides subject to mass spectrometry prior to (b).
• the peptides subject to mass spectrometry in (b) are singly-charged.
• the fragmentation is measured as a b-series peak, a y-series peak, or both.
• the disclosed methods may be carried out with any type of mass spectrometry methods.
• the mass spectrometry for use in the methods described herein include matrix-assisted laser desorption/ionization time-of-flight/time-of-flight (MALDI-TOF/TOF) or liquid chromatography-mass spectrometry/mass-spectrometry (LC-MS/MS).
• the LC-MS/MS comprises electrospray ionization.
• digesting a protein into peptides may be carried out after thermal stressing of the protein followed by enzymatic digestion with a proteolytic enzyme.
• the proteolytic enzyme comprises at least one of chymotrypsin, trypsin, pepsin, papain, or elastase.
• the /soAsp is not adjacent to an asparagine in the amino acid sequence of the protein and/or is not adjacent to a threonine in the amino acid sequence of the protein.
• the isoAsp is adjacent to an adjacent aspartate residue in the amino acid sequence of the protein.
• the adjacent aspartate is isoAsp or L-Asp.
• a threshold level of fragmentation of the peptide is used as a standard for determining whether /soAsp is present in the protein.
• the threshold may be the level of fragmentation of the peptide bond of a control peptide, such as a synthetic peptide.
• the fragmentation of the peptide exceeds the threshold when a b-peak and/or a y-peak of the fragmented peptide bond N-terminal to /soAsp is present.
• the methods described herein further comprise subjecting a control peptide to mass spectrometry, thereby obtaining the fragmentation of the peptide bond of the control peptide.
• the control peptide is not subjected to thermal stressing.
• the control peptide is a synthetic peptide.
• the synthetic peptide may be used for comparison to one or more protein sample(s).
• the threshold is the level of fragmentation of a peptide bond N-terminal to an L-Asp in a control peptide.
• the fragmentation of the peptide bond of the control peptide is provided as an electronically-stored value or is provided from a reference peptide subjected to the same mass spectrometry methods as the protein sample being tested.
• the protein comprises or consists of an antibody, antibody protein product, bispecific T-cell engager (BiTEO) molecule, antibody fragment, antibody fusion peptide or antigen-binding fragment thereof, peptide, growth factor, or cytokine.
• the antibody is a polyclonal or monoclonal antibody.
• antibody protein product refers to any one of several antibody alternatives which in various instances is based on the architecture of an antibody but is not found in nature.
• the antibody protein product has a molecular-weight within the range of at least about 12 kDa - 1 MDa, for example at least about 12 kDa - 750 KDa, at least about 12 kDa - 250 kDa, or at least about 12 kDa - 150 kDa.
• Antibody protein products in some aspects are those based on the full antibody structure and/or those that mimic antibody fragments which retain full antigenbinding capacity, e.g., scFvs, Fabs and VHH/VH (discussed below).
• the smallest antigen binding antibody fragment that retains its complete antigen binding site is the Fv fragment, which consists entirely of variable (V) regions.
• a soluble, flexible amino acid peptide linker is used to connect the V regions to a scFv (single chain fragment variable) fragment for stabilization of the molecule, or the constant (C) domains are added to the V regions to generate a Fab fragment [fragment, antigen-binding].
• Both scFv and Fab fragments can be easily produced in host cells, e.g., prokaryotic host cells.
• Other antibody protein products include disulfide-bond stabilized scFv (ds-scFv), single chain Fab (scFab), as well as di- and multimeric antibody formats like dia-, tria- and tetra-bodies, or minibodies (miniAbs) that comprise different formats consisting of scFvs linked to oligomerization domains.
• minibodies minibodies that comprise different formats consisting of scFvs linked to oligomerization domains.
• the smallest fragments are VHH/VH of camelid heavy chain Abs as well as single domain Abs (sdAb).
• V-domain antibody fragment which comprises V domains from the heavy and light chain (VH and VL domain) linked by a peptide linker of ⁇ 15 amino acid residues.
• VH and VL domain V domains from the heavy and light chain linked by a peptide linker of ⁇ 15 amino acid residues.
• a peptibody or peptide-Fc fusion is yet another antibody protein product.
• the structure of a peptibody consists of a biologically active peptide grafted onto an Fc domain.
• Peptibodies are well-described in the art. See, e.g., Shimamoto et aL, mAbs 4(5): 586-591 (2012).
• antibody protein products include a single chain antibody (SCA); a diabody; a triabody; a tetrabody; bispecific or trispecific antibodies, and the like.
• Bispecific antibodies can be divided into five major classes: BsIgG, appended IgG, BsAb fragments, bispecific fusion proteins and BsAb conjugates. See, e.g., Spiess et aL, Molecular Immunology 67(2) Part A: 97-106 (2015).
• the antibody protein product comprises or consists of a bispecific T cell engager (BiTE®) molecule, which is an artificial bispecific monoclonal antibody.
• BiTE® molecules are fusion proteins comprising two scFvs of different antibodies.
• BiTE® molecules are known in the art. See, e.g., Huehls et aL, Immuno Cell Biol 93(3): 290-296 (2015); Rossi et aL, MAbs 6(2): 381-91 (2014); Ross et aL, PLoS One 12(8): e0183390.
• the methods described herein further comprise determining the position of the /soAsp in the protein.
• the /soAsp is detected during a protein discovery process or during a protein production process.
• absence of the /soAsp indicates suitability of the protein for further processing.
• the method further comprises rejecting the protein when the protein comprises /soAsp. “Rejecting” the protein includes, but is not limited to, halting or revising the protein production or purification process or disposing of the protein supply. If the protein production process is halted, additional processing may be carried out to further assess protein stability, molecular assessment, and/or quality control. In various embodiments, rejecting the protein comprises discarding or disposing of a quantity of product comprising the protein, and/or rejecting a clone that produces the protein. [0017] In various embodiments wherein the method determines the protein comprises /soAsp, the method further comprises engineering the protein to remove the site that is susceptible to /soAsp formation. For example, the engineering comprises inducing a point mutation at the position of the /soAsp in the protein.
• the presence of /soAsp results in structural changes in the peptide backbone compared to a reference protein comprising an L-Asp at the same position.
• the presence of /soAsp inhibits potency of the protein.
• the presence of /soAsp increases the immunogenicity of the protein compared to a reference protein comprising an L-Asp at the same position.
• the disclosure provides for methods of evaluating the potency and/or immunogenicity of a protein by determining whether the protein comprises /soAsp.
• At least one of the peptides comprises a positive charge at the N terminus of the peptide.
• the method further comprises introducing a positive charge to the N terminus of the peptide.
• the positive charge is introduced by incubating the peptide with an N-terminal charge-derivatizing reagent.
• the N-terminal charge- derivatizing reagent is (N-succinimidyloxycarbonylmethyl) tris (2,4,6 trimethoxyphenyl) phosphonium bromide (TMPP) or a derivative thereof.
• the N-terminal charge-derivatizing reagent is tris[2,4,6-trimethoxyphenyl]phosphonium acetyl (TMPP-Ac) or a derivative thereof.
• TMPP-Ac tris[2,4,6-trimethoxyphenyl]phosphonium acetyl
• the /soAsp is within 5 amino acid residues of a C- terminus of at least one of the peptides, for example within 4, 3, 2, or 1 amino acid residues of the C-terminus.
• a mass spectrometry system configured for performing the methods described herein.
• the fragmentation of a peptide bond N-terminal to the /soAsp is measured using the mass spectrometry system disclosed herein.
• the fragmentation exceeding the threshold is indicative of the presence of /soAsp in a protein.
• the disclosure provides for methods of determining the presence of /soAsp in a protein using a mass spectrometry system of the disclosure.
• the mass spectrometry performed is matrix-assisted laser desorption/ionization time-of-flight/time-of-flight (MALDI-TOF/TOF).
• the mass spectrometry performed is liquid chromatography-mass spectrometry/mass- spectrometry (LC-MS/MS), such as electrospray ionization LC-MS/MS.
• “About” or “approximately” means, when modifying a quantity (e.g., “about” 3:1 ratio), that variation around the modified quantity can occur. These variations can occur by a variety of means, such as typical measuring and handling procedures, inadvertent errors, ingredient purity, and the like.
• Figure 1 is a schematic displaying the isomerization pathway of both amino acid residues, aspartic acid and asparagine, via the succinimide intermediate, to form /soaspartic acid. The chirality and equilibrium of each stage was not considered.
• Figures 2A-2F are mass spectra and graphs of matrix-assisted laser desorption/ionization time-of-flight/time-of-f light (MALDI-TOF/TOF) spectrometry performed on standard peptides; Fig. 2A) L/soDA; Fig. 2B) LDA; Fig. 2C) A plot of the ratio y 2 /b 2 against %- /soAsp peptide in a defined mixture of the two tripeptides. Each point represents the average of triplicate measurements.
• Fig. 2D p-Asp DSIP (WAGG/soDASGE; SEQ ID NO: 1 ; Fig.
• Figures 3A-3F are mass spectra showing the identification of peptides containing /soAsp residue from thermal stressed therapeutic mAb by MALDI-TOF/TOF. Each peptide was collected and analyzed by MALDI-TOF/TOF.
• Figures 4A-4B are a series of mass spectra of ESI infusion of the peptides WAGGDASGE (Fig. 4A; SEQ ID NO: 2) and WAGG/soDASGE (Fig. 4B; SEQ ID NO: 1 ) into the Orbitrap Velos Pro showed the unmodified peptide displayed only the singly charged ion.
• Figure 5 is a series of mass spectra of MALDI-TOF/TOF fragmentation of the control (top) and the modified (bottom) peptide.
• the enhancement in the b 9 and the y 8 ions were observed in the /soD peptide. Using the ratio between these two ions in each spectrum, R iS omer was determined to be 1 .8.
• Figure 6 is a series of mass spectra of MALDI TOF/TOF analysis of a synthetic control (top panel) and modified (bottom panel) peptide. Enhancement of the y 9 ion was observed in the isoD peptide. By using the y 9 and y pair for the calculation, R iS omer was determined to be 3.1.
• Figure 7 is a series of mass spectra showing the enhancement of the y 4 ion was readily observed in the modified peptide, indicative that the peptide bond N-terminal to the /soD residue was more easily fragmented in MALDI TOF/TOF.
• Risomer was calculated to be 3.7.
• Figure 8 is a series of mass spectra of MALDI TOF/TOF fragmentation of the pentapeptide ALDGE (top) (SEQ ID NO: 8) and AL/soDGE (bottom) (SEQ ID NO: 9).
• Risomer was determined to be 2.3. It is interesting to note that the b 3 fragment ion in the modified peptide was very much reduced in comparison to the control peptide.
• Figure 9 is a series of mass spectra of MALDI TOF/TOF fragmentation of ALDEK (top) (SEQ ID NO: 10) and AL/soDEK (bottom) (SEQ ID NO: 11 ) shows an enhancement in the y 3 ion in the modified peptide.
• Risomer was determined to be 1 .5.
• the b 3 fragment was essentially not detected in the /soD peptide.
• Figure 10 is a series of mass spectra of MALDI-TOF/TOF fragmentation of ALDGK (top) (SEQ ID NO: 12) and AL/soDGK (bottom) (SEQ ID NO: 13). By using the y 2 and y 3 pair, Risomer was determined to be 2.1 .
• Figure 11 is a series of mass spectra of MALDI-TOF/TOF fragmentation of GLDLLK (top) (SEQ ID NO: 14) and GL/soDLLK (bottom) (SEQ ID NO: 15) showed an enhancement in the y 4 fragment observed with the modified peptide. By using the y 4 and y 2 fragments of each peptide, Risomer was determined to be 2.8.
• Figure 12 is a series of mass spectra of MALDI-TOF/TOF fragmentation of GDLLLK (top) (SEQ ID NO: 16) and G/soDLLLK (bottom) (SEQ ID NO: 17). While the fragment N- terminal to the modified residue (y 5 ) is minimal, it is significantly larger than that detected in the control peptide. Using y 5 and b 4 in the calculation, R iS omer was determined to be 5.8.
• Figures 13A-13B are a series of mass spectra of liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis of the singly charged species (M+H+ ; m/z 1204.48) of the chymotryptic peptide encompassing Asp102 showed the modified peptide gave a very prominent be + H 2 O fragment. The data is very similar to what was observed using MALDI- TOF/TOF.
• Figure 14 is an instrument schematic of the MALDI-TOF/TOF instrument displaying peptide fragmentation and the LIFT technology.
• Figure 15 is a series of chromatograms showing Red/IAM of a heat-stressed antibody protein product Tryptic peptide (XIC of the peptide of interest)
• Figure 16 is a chromatogram showing a heat-stressed antibody protein product Tryp. Peaks P1 , P2 and P4 have the same m/z. P3 is the cyclic imide derivative XDDHXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX. The suspected /soAsp is DD and DH or DDH, with /soAsp residue underlined.
• Figure 17 is an LC chromatographic trypsin map of a heat-stressed antibody protein product following thermal stressing.
• Figure 18 is a chromatogram showing the location of the 4 peptides of interest.
• Figure 19 shows a spectrum following MALDI fragmentation of the peptide of interest derived from the control (unstressed) protein (top panel) and the heat stressed material P1 (bottom panel). In both cases, the ratio of the intensity of y 25 to y 23 is approximately 1 :1 , indicating P1 is the remaining unmodified peptide.
• Figure 20 shows a spectrum following MALDI fragmentation of the peptide derived from heat stressed material P2 (top panel) and P4 (bottom panel).
• P2 heat stressed material
• P4 bottom panel
• y 25 to y 23 was determined to be 1 .7 to 1 , indicating the modification is at isoDH.
• P4 the readily detectable y 26 demonstrates the modification is at isoDD.
• Figure 21 show mass spectra of control versus thermally stressed antibody protein product sample.
• Figures 22A-22B Figure 22A shows MALDI-TOF/TOF fragmentation of GFYPSDIAVEWESNGQPEDNYK (SEQ ID NO: 24) (top panel) & GFYPSDIAVEWESNGQPE/soDNYK (SEQ ID NO: 25) (bottom panel).
• Figure 22B shows MALDI-TOF/TOF fragmentation of the peptide GFYPSDIAVEWESNGQPENDYK (SEQ ID NO: 26) (top panel) & GFYPSDIAVEWESNGQPEN/soDYK (SEQ ID NO: 27) (bottom panel).
• Figure 23A shows MALDI-TOF/TOF fragmentation of TMPP modified GFYPSDIAVEWESNGQPEDNYK (SEQ ID NO: 24) (top panel) & TMPP modified GFYPSDIAVEWESNGQPEisoDNYK (SEQ ID NO: 25) (bottom panel).
• Figure 23B shows MALDI-TOF/TOF fragmentation of TMPP modified GFYPSDIAVEWESNGQPENDYK (SEQ ID NO: 26) (top panel) & TMPP modified GFYPSDIAVEWESNGQPENisoDYK (SEQ ID NO: 27) (bottom panel).
• Figure 24 shows an exemplary structure of (N- Succinimidyloxycarbonylmethyl)tris(2,4,6-trimethoxyphenyl)phosphonium bromide (TMPP).
• the protein is a large peptide/ polypeptide (> 50 amino acids), antibody, antibody protein product, bispecific T cell engager (BiTE®) molecule, antibody fragment, antibody fusion peptide or antigenbinding fragments thereof.
• the method comprises using mass spectrometry to detect /soAsp in a protein.
• the disclosed methods are advantageous, because, in contrast to conventional detection of /soAsp, neither specialized instrumentation nor ion chemistry is required.
• the present disclosure also provides mass spectrometry systems configured for performing the methods disclosed herein.
• the protein has at least two consecutive aspartate residues in its amino acid sequence.
• the method comprises: (a) digesting a protein into peptides, (b) subjecting the peptides to mass spectrometry and measuring fragmentation, by mass spectrometry (such as tandem-mass spectrometry), of a peptide bond N-terminal to an /soAsp; (c) comparing the fragmentation to a threshold, wherein the fragmentation exceeding the threshold is indicative of the presence of the /soAsp in the protein; and (d) rejecting the protein comprising the /soAsp, or engineering the protein to remove the /soAsp.
• mass spectrometry such as tandem-mass spectrometry
• /soAsp refers to an /soAsp residue in the context of a protein or peptide. Further description of the method is provided below. It is contemplated that small amounts of /soAsp may be tolerated for some applications. Accordingly, in some embodiments, (d) comprises rejecting the protein if the /soAsp is at or above a specified level. In some embodiments, the method further comprises introducing a positive charge to the N terminus of the peptides using an N-terminal charge-derivatizing reagent, such as TMPP, prior to subjecting the peptide to mass spectrometry.
• TMPP N-terminal charge-derivatizing reagent
• the method comprises measuring, by mass spectrometry, the fragmentation of a peptide bond N-terminal to an /soAsp residue. Mass spectrometry is used to measure the mass/charge of ions. In some embodiments, the charge is associated with the C-terminal region of the peptide and is known as the “y-series peak” or “y-peak”.
• the charge is associated with the N- terminal region of the peptide and is known as the “b-series peak” or “b-peak”.
• the fragmentation is measured as a b-series peak, a y-series peak, or both.
• the fragmentation of a protein sample is compared to a threshold, where the fragmentation exceeding the threshold is indicative of the presence of the /soAsp in the protein.
• the threshold may be determined by measuring fragmentation of a control peptide or the threshold may be a reference value that is known to correspond with fragmentation of unmodified proteins, such as protein that does not comprise /soAsp.
• the threshold may be based on presence of a b-peak and/or a y-peak of the fragmented peptide bond N-terminal to /soAsp.
• the fragmentation exceeds the threshold when a b-peak and/or a y-peak of the fragmented peptide bond N-terminal to /soAsp is present in the protein sample.
• the fragmentation of a protein sample is compared to the fragmentation to that of a control peptide.
• the control peptide is also referred to as a “reference peptide.”
• the control or reference peptide may be a peptide or protein which does not contain an /soAsp residue or has been engineered to remove /soAsp and/or contain an L-Asp residue.
• the threshold may be based on the level of fragmentation of a peptide bond N-terminal to an L-Asp in a control peptide.
• the threshold refers to a level of fragmentation that is indicative of the presence of at least one /soAsp in a protein or peptide.
• control peptide is optionally subjected to the same method (including (a), (b) and/or (c)) as the protein sample.
• fragmentation of the peptide bond of the control peptide is provided as an electronically-stored value or a reference value.
• An exemplary reference value is based on mass spec data from previously processed proteins that is stored electronically.
• processing software generate electronic rules on isoAsp fragmentation and intensity of fragment ions N-terminal to the /soAsp when compared to a control peptide.
• the control peptide may be a synthetic peptide particularly designed based on the protein being processed.
• control peptide may be a fragment of a protein that does not comprise /soAsp and preferably does not comprise any modified or altered amino acids.
• control protein comprises an L-Asp at the same position as the protein in the sample.
• the disclosed methods comprise digesting a protein sample to be tested, into peptides.
• the digestion may be carried out using any known methods that would digest a protein into peptides.
• digestion of the sample protein may be carried out using enzymatic digestion using a proteolytic enzyme after thermal stressing has been performed.
• Thermal degradation refers to deterioration of polymeric molecules as a result of exposing proteins and/or peptides to increased temperatures, and in some instances excessively high temperatures.
• thermal degradation is carried out at 38-400°C.
• thermal degradation is carried out at 40°C for 2-4 weeks, 3-6 months at 40°C, 1-2 months at 25°C, 1 month at 25°C, 3-6 months at 4°C or 6 months at 4°C.
• thermal degradation is carried out at 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, 50, 55, 60, or 65°C.
• thermal degradation is carried out for 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours or 1 day, 2 days, 3, days, 4 days, 5 days, 6 days, 7 days or 1 week, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days or at least 2 weeks; at least 3 weeks, at least 4 weeks or at least 1 months, at least 5 weeks, at least 6 weeks, at least 8 weeks or at least 2 months, at least 3 months, at least 4 months, at least 5 months, or at least 6 months.
• the thermal degradation is carried out between pH 5-8.
• thermal degradation is carried out at pH 5.0, 5.1 , 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1 , 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1 , 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, or pH 8.0.
• the thermal degradation is performed accordingly to the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines.
• thermal degradation comprises incubation at 40°C for 2-4 weeks (such as 2 weeks) at a pH in a range of pH 5 to pH 8.
• Enzymatic digestion of proteins involves cleaving the peptide bond with an enzyme to form peptides.
• the digestion may be carried out with enzymes having varying degrees of specificity.
• enzymatic digestion may be carried out with one or more proteolytic enzymes.
• proteolytic enzymes include, but are not limited to, chymotrypsin, trypsin, pepsin, papain, or elastase.
• the protein sample may be reduced and alkylated prior to digestion with a proteolytic enzyme and subsequently analyzed by mass spectrometry.
• the protein may be reduced with redox agents such as dithiothreitol (DTT), B-mercaptoethanol and TCEP (Tris (2-carboxyethyl) phosphine).
• the protein may be alkylated with a sulfhydryl reagent such as iodoacetamide (IAM), iodoacetic acid (IAA) or another electrophile to prevent reformation of disulfide linkages.
• IAM iodoacetamide
• IAA iodoacetic acid
• both the protein sample and control sample (control peptide) are digested with a proteolytic enzyme.
• the protein sample is thermally degraded and subsequently analyzed by mass spectrometry.
• introducing a positive charge to the N terminus of the peptide(s) prior to mass spectrometry can enhance the intensity of the peak that identifies fragmentation N-terminal of /soAsp, such as the b n -i+H 2 O peak (where n is the residue number of the /soAsp in the peptide) compared to a reference peptide in which the positive charge is not introduced to the N-terminus (See Example 7).
• the methods disclosed herein may further comprise N-terminal modification of peptides.
• the method further comprises introducing a positive charge to the N terminus of the peptides, prior to mass spectrometry analysis.
• the positive charge is introduced by incubating the peptides with an N-terminal charge-derivatizing reagent.
• An “N-terminal charge- derivatizing reagent” refers to reagents which have the ability add a positive charge to the N terminus of one or more peptides or proteins (i.e. agent which introduce a positively charged group, such as quaternary or tertiary ammonium and quaternary phosphonium groups at the N- terminus of a peptide or protein).
• N-terminal charge-derivatizing reagents which may be used with methods disclosed herein include, but are not limited to, (N- succinimidyloxycarbonylmethyl) tris (2,4,6 trimethoxyphenyl) phosphonium bromide (TMPP), tris[2,4,6-trimethoxyphenyl]phosphonium acetyl (TMPP-Ac), 4-amidinobenzoic acid, nicotinic acid, 2-(6-amidinonaphthalen-2-yloxy)acetic acid, 4-(guanidinomethyl)benzoic acid, or derivatives thereof.
• TMPP 2,4,6 trimethoxyphenyl
• TMPP-Ac tris[2,4,6-trimethoxyphenyl]phosphonium acetyl
• 4-amidinobenzoic acid 4-amidinobenzoic acid, nicotinic acid, 2-(6-amidinonaphthalen-2-yloxy)acetic acid, 4-(guanidino
• TMPP An exemplary structure of TMPP is shown in Figure 24. Without being limited by theory, it is contemplated that TMPP retains a positive charge on its phosphorus atom, permitting the positive charge to be directed to the N terminus of the peptide when the peptide is tagged with TMPP.
• the disclosed method can be carried out with reagents comprising the disclosed structure of TMPP or derivatives thereof. The disclosed method can also be carried out with regents that share a similar structure that adds a positive charge to the N-terminal of the peptide or protein.
• the introduction of a positive charge to the N terminus of one or more peptides may improve the detection of isoaspartate containing peptides by mass spectrometry.
• a N-terminal charge-derivatizing reagent such as TMPP
• an N-terminal charge-derivatizing reagent may be used when the /soAsp is within 5 amino acid residues of a C-terminus of at least one of the peptides.
• the /soAsp may be within 4, 3, 2, or 1 amino acid residues of the C-terminus.
• the mass spectrometry method is MALDI-TOF/TOF.
• N-terminal modification of the peptide using a N-terminal charge- derivatizing reagent such as TMPP, followed by MALDI-TOF/TOF fragmentation results in the detection of a more intense b n -i+H 2 O product ion in the modified peptide when compared to the aspartate counterpart (n denotes the residue number of the isoaspartate in the peptide).
• the method comprises using mass spectrometry to detect /soAsp in a sample.
• Mass spectrometry is used to measure the mass/charge of ions.
• the mass spectrometry comprises or consists of matrix-assisted laser desorption/ionization time-of-flight/time-of-flight (MALDI-TOF/TOF).
• the mass spectrometry comprises or consists of liquid chromatography-mass spectrometry/mass-spectrometry (LC-MS/MS), also referred to as liquid chromatographytandem mass spectrometry.
• MALDI-TOF/TOF mass spectrometry is used to characterize and determine the position of /soAsp residues in synthetic peptides and proteolytically generated peptides from a protein sample.
• LC-MS/MS mass spectrometry may be used. Without being limited by theory, it is contemplated that MALDI-TOF can be used in methods described herein with charge reduction. For methods comprising LC-MS/MS, the mass spectrometry may be preceded by charge reduction.
• the methods described herein further comprise charge reduction of the peptide sample prior to (b).
• Charge reduction Smith. J Am Soc Mass Spectrom 2008, 19(5), 629-31 , which is incorporated by reference in its entirety
• the peptides subject to mass spectrometry in (b) are singly-charged.
• the term “singly-charged” refers to peptide with +1 or -1 charge state.
• the fragmentation is measured as a b-series peak, a y-series peak, or both.
• charge reduction refers to decreasing the magnitude of the charge of the peptide, so as to decrease the number of charged species in the peptide, which may make the charge state of the peptide neutral (or closer to neutral).
• the charge of peptide is reduced by making it smaller (e.g. by enzymatic digestion).
• the charge of peptide is reduced by a favorable addition (e.g. the use of a basic chemical).
• charge reduction can be performed in the following ways. Firstly, the length of the peptide is reduced by using an enzyme other than trypsin, such as chymotrypsin. The resulting peptide would be smaller and therefore possess less charge.
• the present disclosure also provides mass spectrometry systems configured for performing the methods disclosed herein.
• the fragmentation of a peptide bond N-terminal to the /soAsp is measured using the mass spectrometry system disclosed herein.
• the fragmentation of a peptide bond N-terminal to the /soAsp exceeding the threshold is indicative of the presence of /soAsp in a protein.
• the mass spectrometry system is MALDI-TOF/TOF.
• the mass spectrometry system is LC-MS/MS.
• the mass spectrometry system uses higher energy collisional dissociation (HCD).
• the protein sample (which, for conciseness, may also be referred to herein simply as a “protein”) comprises any type of protein that may be processed or analyzed for stability and/or structural integrity.
• the protein sample so subjected to the methods disclosed herein comprises or consists of a large peptide, antibody, antibody fragment, antibody fusion peptide or antigen-binding fragments thereof.
• the antibody is a polyclonal or monoclonal antibody.
• Aspartic acid (Asp) to /soaspartic acid (/soAsp) isomerization in therapeutic monoclonal antibodies (mAbs) and other biotherapeutics is a critical quality attribute (CQA) which requires careful control and monitoring during the discovery and production processes.
• CQA critical quality attribute
• the unwanted formation of /soAsp within biotherapeutics and resultant structural changes in the peptide backbone may negatively impact the molecule activity or become immunogenic, especially if the isomerization occurs within the complementarity determining region (CDR).
• the methods disclosed herein may be used to monitor /soAsp during the protein discovery (Research) process or a protein production (Process Development) process.
• an absence of the /soAsp indicates suitability of the protein for further processing.
• the presence of /soAsp may result in one or more of the following changes to the protein: structural changes in the peptide backbone, change the protein activity, or increase the immunogenicity.
• the presence of /soAsp results in structural changes in the peptide backbone compared to a reference protein comprising an L-Asp at the same position.
• the presence of /soAsp inhibits potency of the protein.
• the presence of /soAsp increases the immunogenicity of the protein compared to a reference protein comprising an L-Asp at the same position.
• protein e.g., a sample, clone, lot, or batch comprising the protein
• the protein may be rejected if the protein contains excessive amount of /soAsp (typically about 5% in the Research Discovery stage)
• rejecting the protein comprising the /soAsp comprises rejecting a quantity of product comprising the protein, or rejecting a clone that produces the protein.
• the method further comprises reducing or inhibiting /soAsp by protein engineering.
• the method further comprises engineering the protein to remove the site that is susceptible to aspartate isomerization comprises inducing a point mutation at the position of a nucleic acid encoding the /soAsp in the protein.
• the protein comprising the /soAsp is rejected if the /soAsp is at or above a specified level.
• Aspartic acid (Asp) to /soaspartic acid (/soAsp) isomerization in therapeutic monoclonal antibodies (mAbs) and other biotherapeutics is a critical quality attribute (CQA) which requires careful control and monitoring during the discovery and production processes.
• CQA critical quality attribute
• the unwanted formation of /soAsp within biotherapeutics and resultant structural changes in the peptide backbone may negatively impact the molecule activity or become immunogenic, especially if the isomerization occurs within the complementarity determining region (CDR).
• Racemization at the aspartate residue is also possible during the process, resulting in the formation of both D-/soAsp and D-Asp.
• racemization is relatively rare and racemized amino acids have been detected in long-lived proteins such as lens crystallins and tooth dentine 20-21 22 .
• Repairing /soAsp residues in modified cellular proteins is crucial and an enzyme that partially converts /soAsp residues in proteins (protein L-/soaspartyl methyl transferase PIMT) back to aspartate has been identified in microbial, mammalian and plant systems 23-24 . A detailed review on the biology and the substrate specificity of this enzyme has been published 25 (incorporated by reference in its entirety).
• /soAsp can be identified by automated Edman degradation where the Edman chemistry would terminate at the modified residue 40 .
• N-terminal sequencing is time consuming, requiring a larger amount of material when compared to LC-MS/MS.
• Lehmann 41 reported the use of LC-MS/MS to analyze /soAsp in peptides and demonstrated that complementary b/y ion intensity ratios obtained by fragmentation of the (Asp//soAsp)-X bond could be employed to distinguish between the modified residue from its unmodified counterpart.
• the MS/MS data presented by Bondarenko and co-workers 42 suggested the observation made by Lehmann, may not be applicable to all /soAsp containing peptides.
• the intensity of the yL-n+1 is increased compared to a corresponding peptide containing L-Asp.
• the authors attributed this observation to the shorter /soaspartyl side chain interacting with the carbonyl group in the peptide bond N-terminal to the modified residue.
• Fuji et al. utilized Post source decay-matrix assisted laser desorption ionization (MALDI-PSD) to evaluate the amount of /soAsp formation from a tryptic digest of human aged lens crystallin; a relatively small protein.
• MALDI-PSD Post source decay-matrix assisted laser desorption ionization
• the methods disclosed herein are able to detect /soAsp in larger peptides and proteins with consecutive aspartate residues.
• RDD radical directed dissociation
• the carboxylate side chain was modified with carbodiimide to obtain acylisourea. Subsequent 1 ,3-acyl shift led to the formation of N-acylurea. Under collision induced dissociation (CID) conditions, distinct fragments of acylisourea and N- acylurea can be detected. However, because of steric hindrance imposed by the /soAsp side chain, formation of N-acylurea is not favored. Thus, the predominant fragment observed with the modified peptide was that derived from acylisourea.
• CID collision induced dissociation
• the methods disclosed herein may be used to determine the position of /soAsp residues in a protein.
• the disclosed herein may be used for quality control during the protein production process.
• the disclosed method may also be used to assess stability or structural stability of the protein after storage or exposure to temperature changes, light or other environmental or chemical factors.
• the delta-sleep inducing peptides DSIP and -Asp DSIP (WAGGDASGE (SEQ ID NO: 2) and WAGG/soDASGE (SEQ ID NO: 1 ) were purchased from Bachem (Torrance, CA).
• the MS grade proteolytic enzymes chymotrypsin and trypsin were purchased from Thermos Scientific (Waltham, MA).
• Dithiothreitol (DTT) and iodoacetamide (IAM) were obtained from Sigma Aldrich (St Louis, MO).
• the MALDI matrix used (4-HCCA) was from Broker Daltonics (Billerica, MA). All other reagents used were of the highest grade commercially available. Optima LC-MS grade solvents were used throughout.
• the therapeutic mAb at a concentration of 1 .26 mg/mL was incubated in 0.1 M ammonium bicarbonate (pH 7.8) at 40°C for 2 weeks to induce aspartate isomerization.
• the sample was reduced (DTT) and alkylated (IAM) prior to digestion with trypsin or chymotrypsin and subsequent LC-MS/MS analysis.
• MALDI-MS was performed by using a Bruker UltrafleXtremeTOF/TOF mass spectrometer, equipped with a 2,000 Hz smartbeam II (Nd:YAG) laser. 4-HCCA was used as the matrix (saturated solution in 0.1 % TFA/50% acetonitrile).
• the column used was an Acquity UPLC peptide BEH C18 (2.1 x 150 mm, 1 .7 pm) column.
• Solvent A was 0.1 % formic acid in water and solvent B was 0.1 % formic acid in acetonitrile.
• the column was equilibrated in 1 % B at a flow rate of 0.25 mL/min and at 50°C. Upon sample application, the column was washed with 1 % B for 8 min before a linear gradient from 1 to 55 % B over 70 min was applied. Peptide elution was monitored by absorbance at 214 nm and the eluted peptides were introduced into a Q-Exactive for MS and MS/MS.
• a spray voltage of 3.5 kV was used.
• the data-dependent MS method consisted of a full MS from m/z 300-2000 at a resolution of 70,000. This was followed by HCD (at resolution 17,500) of the 10 most abundant precursors.
• AGC target values were set at 1 E6 for full MS and 5e4 for HCD.
• An isolation width of 2 Da and a NCE of 27 were employed.
• the tandem MS data obtained was analyzed by for peptide identification.
• Figure 2A & 2B provide the MALDI-TOF/TOF data obtained for tripeptides L/soDA and LDA respectively.
• L/soDA peptide the predominant ion (y 2 ) demonstrated fragmentation at the bond N-terminal to the /soAsp residue is preferred.
• the aspartyl peptide clearly demonstrated that the major cleavage site was after the aspartate residue with the generation of b 2 ion, which is attributed to the “aspartate-effect” 67 .
• EXAMPLE 2 Identification of IsoAspartate in Thermal Stressed mAb [0088] To put the above observations into the context of a real-life therapeutically relevant mAb, the MALDI-TOF/TOF method was used to identify an isomerized Asp residue in a mAb after thermally induced forced degradation. It has been well documented that a commercial mAb has an Asp residue at position 102 in the CDR3 domain of its heavy chain that has the propensity to undergo isomerization and modification of which results in loss of activity 37 69 .
• the mAb was incubated in pH 7.8 and at 40°C for 2 weeks followed by reduction, alkylation and tryptic digestion. An unstressed mAb treated under identical conditions was used as control. Upon thermal stressing, other modifications such as Asn deamidation and Met oxidation were also present. Because they have been previously identified and documented by others 70 , Asn deamination and Met oxidation were not examined in these sets of experiments. Therefore, this disclosure describes characterization of heavy chain CDR3 Asp102 isomerization.
• Figure 3A shows the LC-UV tryptic map of the thermal stressed mAb (zoomed in to the region of interest).
• Analysis of the LC-MS/MS data demonstrated the tryptic peptide encompassing heavy chain Asp102 (W99GGDGFYAMDYWGQGTLVTVSSASTK124; SEQ ID NO: 3) were eluted in two well resolved peaks (Figure 3A) with identical m/z values, 1392.63 ([M+2H]2+).
• the ratio of the first peak to the second peak is approximately 1 :1 .
• the ratio of the two fragments y 23 and y 24 of each peptide was determined and the Risomer 50 of the two peptides was calculated to be 2.04.
• the increase in the intensity of the y 22 ion shows the peptide bond C-terminal to the /soAsp side chain was more labile to fragmentation under the conditions employed.
• the data therefore demonstrates the order of elution from a RP- HPLC column cannot be used to definitively identify the /soAsp containing peptide from its unmodified counterpart, as in this case, the /soAsp containing peptide was eluted later.
• the antibody at 1 .26 mg/mL was incubated in 0.1 M ammonium bicarbonate (pH 7.8) at 40°C for 2 weeks prior to being frozen at -70°C for further experiments.
• 100 pL of the incubated antibody was dried by vacuum centrifugation.
• the sample was dissolved in 50 pL of 8 M urea in 0.1 M Tris at pH 7.5 before being reduced with 10 mM DTT at 50°C for 1 hr and followed by alkylation with 20 mM iodoacetamide in the dark for 30 min at room temperature. Alkylation was quenched by the addition of DTT.
• the sample was diluted with 150 pL of 0.1 M Tris at pH 7.5 and either digested with 1 % by weight of trypsin or chymotrypsin. Another aliquot of the antibody that has not been subjected to thermal stressing was treated in an identical fashion served as the control. Another set of heat stressed experiments was performed by incubating the antibody in pH 5.2. The amount of heavy chain Asp102 isomerization was similar and only the data at pH 7.8 was provided here.
• MALDI-MS was performed by using a Bruker UltrafleXtremeTOF/TOF mass spectrometer, equipped with a 2,000 Hz smartbeam II (Nd:YAG) laser. 4-HCCA was used as matrix (10 mg/mL in 0.1 % TFA/50% acetonitrile). 1 pL of peptide was mixed with an equivolume of matrix before 1 pL of the mixture was spotted on an MTP 384 ground steel target plate, air-dried and inserted into the instrument for mass measurement. The mass spectrometer was set in the positive mode using a 21 kV acceleration voltage and a 25 kV reflectron voltage.
• the laser power was optimized and in a typical experiment, 5,000 laser shots were accumulated to create the spectra. Fragmentation of selected peptides was recorded using the LIFT cell technology. An initial acceleration voltage of 7.5 kV and a LIFT cell acceleration voltage of 19 kV were employed. Laser power for both the precursors and the fragments were optimized. Usually, about 8,000 to 10,000 laser shots were used in recording the fragmentation data.
• Online LC-MS/MS identification refers to utilizing electrospray ionization and online chromatographic separation of digested peptides followed by MS and MS/MS detection and fragmentation respectively.
• a potential limitation of this MALDI-TOF/TOF method is that the Asp and /soAsp containing peptide must display chromatographic separation, therefore allowing collection and subsequent MALDI-TOF/TOF analysis. However, if chromatographic separation can be achieved, /soAsp determination is straight forward and unequivocal.
• N-terminal charge-derivatizing reagent such as TMPP
• MALDI-TOF/TOF allows a rapid and unequivocal identification of the /soAsp residue even if it is proximal to the C- terminus.
• Roher et aL Structural alterations in the peptide backbone of betaamyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem 1993, 268 (5), 3072- 83. 29. Lambeth, T. R.; Riggs, D. L.; Talbert, L. E.; Tang, J.; Coburn, E.; Kang, A. S.; Noll, J.; Augello, C.; Ford, B. D.; Julian, R. R., Spontaneous Isomerization of Long-Lived Proteins Provides a Molecular Mechanism for the Lysosomal Failure Observed in Alzheimer's Disease. ACS Cent Sci 2019, 5 (8), 1387-1395.

Landscapes

• Life Sciences & Earth Sciences (AREA)
• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Molecular Biology (AREA)
• Physics & Mathematics (AREA)
• Hematology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Bioinformatics & Computational Biology (AREA)
• Chemical & Material Sciences (AREA)
• Urology & Nephrology (AREA)
• Biomedical Technology (AREA)
• Immunology (AREA)
• Spectroscopy & Molecular Physics (AREA)
• Biochemistry (AREA)
• Biotechnology (AREA)
• Microbiology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Biophysics (AREA)
• Food Science & Technology (AREA)
• Medicinal Chemistry (AREA)
• Analytical Chemistry (AREA)
• Cell Biology (AREA)
• General Health & Medical Sciences (AREA)
• General Physics & Mathematics (AREA)
• Pathology (AREA)
• Optics & Photonics (AREA)
• Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Priority Applications (8)

Applications Claiming Priority (4)

Publications (1)

Family

ID=78621972

Family Applications (1)

Country Status (10)

Families Citing this family (1)

Family Cites Families (3)

• 2021
  • 2021-09-30 TW TW110136572A patent/TWI907533B/zh active
  • 2021-09-30 WO PCT/US2021/052783 patent/WO2022072583A1/en not_active Ceased
  • 2021-09-30 ES ES21807318T patent/ES3059573T3/es active Active
  • 2021-09-30 EP EP21807318.7A patent/EP4222500B1/en active Active
  • 2021-09-30 MX MX2023003862A patent/MX2023003862A/es unknown
  • 2021-09-30 AU AU2021351498A patent/AU2021351498A1/en active Pending
  • 2021-09-30 US US18/245,004 patent/US20230366889A1/en active Pending
  • 2021-09-30 CN CN202180067521.7A patent/CN116348770A/zh active Pending
  • 2021-09-30 JP JP2023519654A patent/JP2023546796A/ja active Pending
  • 2021-09-30 CA CA3196920A patent/CA3196920A1/en active Pending

Non-Patent Citations (83)

Also Published As

Similar Documents

Legal Events